Among Medicare-eligible adults considering GLP-1 therapy, the highest-risk subgroups for adverse outcomes from inadequately monitored weight loss include: Adults 75 and older, particularly those with pre-existing frailty or recent unintentional weight loss Postmenopausal women with pre-existing osteopenia or osteoporosis who are not on bone-protective therapy Adults with pre-existing sarcopenia identified by prior weakness, gait slowing, or history of falls People with low protein intake due to food insecurity, dental problems, or swallowing difficulties Those taking multiple medications that interact with the cardiovascular effects of rapid weight loss, including antihypertensives and diuretics that may require dose adjustments as weight decreases Symptoms and Warning Signs to Watch For Older adults beginning GLP-1 therapy should watch for and report the following to their prescribing physician promptly: Rapid or unexpected weight loss (more than 1.5 kg or 3.3 lbs per week) Increased weakness, difficulty rising from a chair without arm support, or balance problems Falls or near-falls Reduced grip strength or difficulty with tasks requiring hand strength Poor appetite or inability to meet daily protein targets despite nutritional counseling Any fracture following minimal trauma What You Can Do Now For Medicare beneficiaries considering the GLP-1 Bridge Program: Before starting, ask your physician to assess your current muscle mass and strength
One of our most popular treatments is the semaglutide injection, a revolutionary weight management drug that helps to reduce appetite and control cravings
Once-weekly dosing is the only schedule studied and approved for tirzepatide
Compound Overview Class of Compound: Peptide Mechanism of Action: Semaglutide is a synthetic version of glucagon-like peptide-1 (GLP-1) and thus mimics the action of this human incretin
However, it is currently inconclusive what specific roles ferroptosis exerts during the development of the skin and appendages, as well as in the pathophysiological processes of cutaneous diseases
Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al
